Savene (Dexrazoxane): Uses, Dosage & Side Effects
Antidote for anthracycline chemotherapy extravasation in adults
Quick Facts About Savene
Key Takeaways
- Savene (dexrazoxane) is the only approved specific antidote for anthracycline chemotherapy extravasation in adults.
- Treatment must begin within 6 hours of the extravasation event, administered as three consecutive daily IV infusions.
- The most common side effects include nausea, injection site reactions, and decreased blood cell counts.
- Savene is not approved for use in children or adolescents under 18 years of age.
- Patients must use effective contraception during treatment and for six months afterward due to potential reproductive risks.
What Is Savene and What Is It Used For?
Quick Answer: Savene (dexrazoxane) is a cytoprotective antidote used to treat anthracycline extravasation in adults. It works by chelating intracellular iron to reduce free radical-mediated tissue damage when anthracycline chemotherapy drugs accidentally leak from a vein into surrounding tissue.
Savene contains the active substance dexrazoxane, which belongs to a class of medications known as cytoprotective agents. It functions as an antidote specifically designed to counteract the tissue-damaging effects of anthracycline chemotherapy drugs. Anthracyclines, which include widely used cancer medications such as doxorubicin, epirubicin, daunorubicin, and idarubicin, are among the most effective chemotherapeutic agents available. However, they carry a well-documented risk of severe tissue injury if they leak from the intended intravenous route into surrounding tissues.
Most anticancer drugs are administered intravenously, typically through a peripheral vein or a central venous catheter. Despite best practices and careful nursing techniques, extravasation events can still occur. Extravasation refers to the accidental leakage of an intravenous drug from the vein into the perivascular or subcutaneous tissue. When this happens with anthracyclines, the consequences can be devastating. These drugs are classified as vesicants, meaning they can cause blistering, tissue necrosis (death of tissue), and ulceration that may extend deep into underlying structures including muscle and tendons.
The mechanism by which anthracyclines cause tissue damage involves the generation of reactive oxygen species (free radicals) through iron-dependent pathways. Dexrazoxane works by penetrating cell membranes and undergoing intracellular hydrolysis to produce a ring-opened form that chelates (binds) iron ions. By removing the iron that anthracyclines need to generate damaging free radicals, dexrazoxane effectively prevents or limits the cascade of tissue destruction that would otherwise occur at the extravasation site.
Clinical studies have demonstrated that Savene significantly reduces the need for surgical debridement (removal of damaged tissue) following anthracycline extravasation. In pivotal clinical trials, treatment with Savene prevented the development of tissue necrosis in the majority of patients who experienced anthracycline extravasation, with most patients able to continue their planned chemotherapy cycles without interruption. The European Medicines Agency (EMA) approved Savene based on evidence from two prospective, open-label, multicenter studies that demonstrated its efficacy in preventing tissue necrosis.
How Savene Works: Mechanism of Action
Dexrazoxane is a cyclic derivative of ethylenediaminetetraacetic acid (EDTA) that can penetrate cell membranes, unlike EDTA itself. Once inside cells, dexrazoxane is enzymatically hydrolyzed to produce ADR-925, its ring-opened metabolite. ADR-925 is a strong chelator of divalent metal ions, particularly iron (Fe2+ and Fe3+). By binding intracellular iron, dexrazoxane prevents the formation of iron-anthracycline complexes and the subsequent generation of hydroxyl radicals through Fenton chemistry. This mechanism interrupts the destructive oxidative cascade at the tissue level, thereby preserving cellular integrity at the extravasation site.
What Should You Know Before Receiving Savene?
Quick Answer: Before receiving Savene, your healthcare team must know about any allergies, liver or kidney problems, pregnancy or breastfeeding status, and all medications you are taking. Savene is contraindicated in patients allergic to dexrazoxane, those who are pregnant or breastfeeding, and those receiving yellow fever vaccine.
Savene is exclusively administered in a hospital setting under the supervision of a physician experienced in cancer treatment. Before treatment begins, your medical team will assess your eligibility for Savene therapy. Several important factors must be considered to ensure safe and effective treatment. Understanding these factors is essential for all patients and their caregivers.
Contraindications
Savene must not be used in the following situations:
- Hypersensitivity: If you are allergic to dexrazoxane or any other ingredients in Savene (including the diluent solution components such as sodium chloride, potassium chloride, magnesium chloride hexahydrate, sodium acetate trihydrate, and sodium gluconate).
- Pregnancy planning without contraception: If you are planning to become pregnant and are not using effective contraception methods.
- Breastfeeding: Savene must not be administered to patients who are breastfeeding.
- Yellow fever vaccination: Patients receiving or planning to receive yellow fever vaccine must not use Savene.
Warnings and Precautions
Several precautions are important during Savene treatment. Your healthcare team will carefully monitor you throughout the treatment course:
- Extravasation confirmation: Savene should only be given if you have experienced a confirmed extravasation event during anthracycline chemotherapy.
- Extravasation site monitoring: The area where the extravasation occurred will be examined regularly during and after treatment to assess healing and detect any complications.
- Blood monitoring: Regular blood tests will be performed to check your blood cell counts, as Savene can cause myelosuppression (decreased production of blood cells).
- Liver function: If you have liver problems, your physician will monitor liver function during treatment, as dexrazoxane is metabolized partially through hepatic pathways.
- Kidney function: If you have kidney impairment, dose adjustments may be necessary, and your doctor will monitor for changes in blood cell counts more closely.
Pregnancy and Breastfeeding
Savene poses significant risks to reproductive health, and strict precautions are mandatory:
- Pregnancy: Savene must not be administered during pregnancy. Animal studies have shown potential for embryotoxicity and teratogenicity. If you are pregnant or suspect you may be pregnant, inform your healthcare team immediately.
- Breastfeeding: You must not breastfeed during Savene treatment. It is unknown whether dexrazoxane or its metabolites pass into breast milk, but given the drug's mechanism of action, a risk to the nursing infant cannot be excluded.
- Contraception: Both male and female patients who are sexually active must use effective contraception during treatment and for at least six months after the last dose of Savene.
- Fertility: There is limited information about the effects of Savene on human fertility. Patients with concerns about future fertility should discuss this with their oncologist before treatment.
Driving and Using Machines
Dizziness, fatigue, and syncope (fainting) have been reported in a small number of patients treated with Savene. These side effects may impair your ability to drive or operate machinery. Patients should exercise caution and avoid these activities if they experience any of these symptoms during or after treatment.
How Does Savene Interact with Other Drugs?
Quick Answer: Savene has clinically significant interactions with vaccines (especially yellow fever and live virus vaccines), DMSO topical products, phenytoin, anticoagulants, immunosuppressants (ciclosporin, tacrolimus), and other myelosuppressive agents. These interactions can affect drug efficacy or increase the risk of adverse effects.
Informing your healthcare team about all medications you are currently taking, have recently taken, or might take is essential before receiving Savene. Drug interactions can alter the effectiveness or safety profile of Savene and concomitant medications. The following interactions are of particular clinical significance.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Yellow fever vaccine | Risk of fatal generalized vaccine disease | Contraindicated — must not be used together |
| Live virus vaccines | Risk of systemic, potentially fatal vaccine disease | Not recommended — use inactivated vaccines when possible |
| DMSO (dimethyl sulfoxide) | May interfere with efficacy of Savene | Do not use DMSO topical products concurrently |
Other Important Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Phenytoin | Savene may reduce the effectiveness of phenytoin | Monitor phenytoin levels; dose adjustment may be needed |
| Anticoagulants (e.g., warfarin) | Increased anticoagulant effect; increased bleeding risk | More frequent INR/coagulation monitoring required |
| Ciclosporin | Enhanced immunosuppression | Close monitoring for signs of infection and toxicity |
| Tacrolimus | Enhanced immunosuppression | Close monitoring for signs of infection and toxicity |
| Myelosuppressive agents | Additive bone marrow suppression | Regular blood count monitoring; dose adjustments may be needed |
The interaction with DMSO deserves particular attention. DMSO has historically been used as a topical treatment for anthracycline extravasation in some institutions. However, when Savene (dexrazoxane) is the chosen treatment, DMSO must not be applied to the extravasation site, as it may interfere with the efficacy of dexrazoxane. This represents a critical clinical decision point, and medical teams should establish clear protocols regarding which treatment approach will be used.
What Is the Correct Dosage of Savene?
Quick Answer: Savene is dosed based on body surface area (BSA). The standard adult dosage is 1,000 mg/m² on Day 1 and Day 2, followed by 500 mg/m² on Day 3. Each dose is administered as a 1-2 hour intravenous infusion. The first dose must be given within 6 hours of the extravasation event.
Savene is always administered under the supervision of a physician experienced in cancer treatment. The dose is calculated based on your height, weight, and kidney function. Your physician will determine your body surface area (BSA) in square meters (m²) to calculate the appropriate dose. Precise dosing is essential for optimal therapeutic benefit.
Adults (Normal Kidney Function)
Standard 3-Day Treatment Protocol
| Day | Dose | Infusion Duration | Key Notes |
|---|---|---|---|
| Day 1 | 1,000 mg/m² | 1–2 hours | As soon as possible, within 6 hours of extravasation |
| Day 2 | 1,000 mg/m² | 1–2 hours | Same time as Day 1 infusion |
| Day 3 | 500 mg/m² | 1–2 hours | Same time as Day 1 infusion |
Patients with Kidney Problems
If you have moderate to severe kidney impairment (creatinine clearance below 40 ml/min), your physician will reduce the dose by 50%. Kidney function affects the elimination of dexrazoxane from the body, so dose adjustment is necessary to prevent excessive drug accumulation and associated toxicity. Regular monitoring of blood counts is particularly important in patients with renal impairment.
Children and Adolescents
Savene is not approved for use in patients under 18 years of age. The safety and efficacy data in the pediatric population are insufficient to support a dosing recommendation. If anthracycline extravasation occurs in a pediatric patient, alternative management protocols should be followed under the guidance of a pediatric oncologist.
Administration Details
Several important aspects of Savene administration deserve attention:
- Timing is critical: The first infusion must begin as soon as possible and within the first 6 hours following the anthracycline extravasation. Delays beyond this window may significantly reduce the protective effect of the medication.
- Infusion site: Savene must be infused through a vein in the opposite arm or a different anatomical area from the extravasation site. Using a vein near the damaged area could worsen tissue injury.
- Consistency: The infusion should be administered at the same time each day throughout the 3-day treatment course.
- Single course: Savene is given as a single 3-day treatment course for each extravasation event. It is not continued beyond the three days and is not given again at the next anthracycline chemotherapy cycle unless another extravasation occurs.
- Cooling measures: Any local cooling measures (ice packs) applied to the extravasation site should be removed at least 15 minutes before the Savene infusion to ensure adequate blood flow for drug delivery.
Overdose
If more Savene is administered than prescribed, the patient will be closely monitored for changes in blood cell counts, gastrointestinal effects, skin reactions, and hair loss. These effects are expected extensions of the drug's pharmacological activity. Treatment is supportive, as there is no specific antidote for dexrazoxane overdose. If Savene solution comes into contact with the skin, the affected area should be thoroughly rinsed with water immediately.
What Are the Side Effects of Savene?
Quick Answer: Like all medicines, Savene can cause side effects. The most common include nausea, injection site reactions, decreased white blood cells and platelets, and infections. Serious allergic reactions (anaphylaxis) have been reported rarely. Most side effects are manageable under medical supervision.
As with all medications, Savene can cause side effects, although not all patients experience them. Many of the side effects reported during Savene treatment may also be attributable to the underlying anthracycline chemotherapy and the patient's cancer. Your healthcare team will monitor you carefully and manage any side effects that arise. It is important to report any new or worsening symptoms promptly.
Very Common
May affect more than 1 in 10 people
- Nausea
- Injection site reactions (pain, redness, swelling, hardening at the injection site)
- Decreased white blood cell count (neutropenia)
- Decreased platelet count (thrombocytopenia)
- Infections (post-operative or other infections)
Common
May affect up to 1 in 10 people
- Vomiting
- Diarrhea
- Fatigue, drowsiness, dizziness, syncope (fainting)
- Impaired vision, smell, hearing, touch, or taste
- Fever
- Phlebitis (inflammation of a vein)
- Superficial thrombophlebitis (inflamed vein with blood clot near the skin surface)
- Deep vein thrombosis (blood clot in a vein, usually in an arm or leg)
- Mouth inflammation (stomatitis)
- Dry mouth
- Hair loss (alopecia)
- Itching (pruritus)
- Weight loss, decreased appetite
- Muscle pain, tremor
- Vaginal bleeding
- Breathing difficulties (dyspnea)
- Pneumonia
- Swelling of arms or legs (edema)
- Wound complications
- Altered liver function (seen in blood test results)
Frequency Unknown
Reported but frequency cannot be estimated from available data
- Allergic reactions (anaphylaxis) including rash, swelling, wheezing, difficulty breathing, low blood pressure, loss of consciousness
It is important to understand that many of these side effects overlap with symptoms caused by the underlying cancer and concurrent chemotherapy treatment. Your oncology team has extensive experience in distinguishing between treatment-related side effects and disease-related symptoms. Regular blood tests and clinical assessments during and after the 3-day treatment course will help identify and manage any adverse effects promptly.
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorized is vitally important. It allows continuous monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority. In the European Union, reports can be made through national reporting systems accessible via the EMA website.
How Should Savene Be Stored?
Quick Answer: Savene powder and diluent should be stored at or below 25°C (77°F), protected from light in the original packaging. After reconstitution and dilution, the solution is stable for 4 hours at 2-8°C (refrigerated), but ideally should be used immediately.
Proper storage of Savene is essential to maintain its efficacy and safety. As a hospital-use medication, storage is managed by pharmacy and nursing staff, but understanding the requirements provides important context for all stakeholders involved in patient care.
- Before reconstitution: Store at or below 25°C (77°F). Keep the powder vials and diluent bottles in the outer carton to protect from light.
- After reconstitution and dilution: Chemical and physical stability has been demonstrated for 4 hours when stored at 2-8°C (refrigerated). However, to minimize the risk of microbial contamination, the product should ideally be used immediately after preparation.
- Expiry date: Do not use after the expiry date printed on the carton, the powder vial label, and the diluent bottle label. The expiry date refers to the last day of the stated month.
- Keep out of the sight and reach of children.
What Does Savene Contain?
Quick Answer: Each Savene vial contains 500 mg of dexrazoxane (as 589 mg dexrazoxane hydrochloride). The diluent solution contains sodium chloride, potassium chloride, magnesium chloride hexahydrate, sodium acetate trihydrate, sodium gluconate, sodium hydroxide, and water for injection.
Active Ingredient
The active substance is dexrazoxane. Each powder vial contains 500 mg of dexrazoxane, present as 589 mg of dexrazoxane hydrochloride. After reconstitution with 25 ml of the Savene diluent solution, the concentration is 20 mg/ml. The reconstituted concentrate appears slightly yellow.
Other Ingredients (Diluent Solution)
The Savene diluent is a sterile, electrolyte-containing aqueous solution with the following components:
- Sodium chloride
- Potassium chloride
- Magnesium chloride hexahydrate
- Sodium acetate trihydrate
- Sodium gluconate
- Sodium hydroxide (for pH adjustment)
- Water for injection
Packaging
Savene is supplied as an emergency treatment kit containing 10 vials of Savene powder (white to off-white) and 3 bottles of Savene diluent solution, together with 3 bottle hangers for infusion. This packaging is designed to provide sufficient material for a complete 3-day treatment course for most adult patients.
The manufacturer and marketing authorization holder is CNX Therapeutics Ireland Limited, Dublin, Ireland. The product is manufactured by Cenexi-Laboratoires Thissen SA, Braine-L'Alleud, Belgium.
Frequently Asked Questions About Savene
Anthracycline extravasation occurs when chemotherapy drugs from the anthracycline class (such as doxorubicin, epirubicin, or daunorubicin) accidentally leak from the intended intravenous route into the surrounding tissue. This is considered a medical emergency because anthracyclines are vesicant agents, meaning they can cause severe blistering, tissue necrosis (cell death), and deep ulceration that may require surgical intervention including skin grafting. The tissue damage can extend to muscles, tendons, and nerves, potentially resulting in permanent functional impairment. Savene is specifically designed to prevent or minimize this tissue destruction when administered promptly.
Clinical studies have shown that Savene is highly effective at preventing tissue necrosis from anthracycline extravasation. In the two pivotal clinical trials that led to its approval, Savene treatment prevented the need for surgical debridement in the vast majority of patients. Most patients were able to continue their planned chemotherapy schedule without significant delay. The key factor in Savene's effectiveness is timely administration — treatment must begin within 6 hours of the extravasation event for optimal results.
No, Savene is specifically approved only for the treatment of anthracycline extravasation. Its mechanism of action — iron chelation to prevent anthracycline-mediated free radical damage — is specific to the way anthracyclines cause tissue injury. Extravasation of other vesicant chemotherapy agents (such as vinca alkaloids, taxanes, or platinum compounds) requires different management approaches. Always follow your institution's extravasation management protocol for the specific drug involved.
DMSO (dimethyl sulfoxide) is an alternative topical treatment that has been used for anthracycline extravasation. However, it must not be used concurrently with Savene because the two treatments may interfere with each other's efficacy. Clinical evidence supports the use of dexrazoxane (Savene) as the preferred treatment when available, as it acts systemically and has demonstrated superior outcomes in clinical trials. When Savene is chosen as the treatment, DMSO must not be applied to the extravasation site at any point during the treatment course.
One of the significant benefits of Savene treatment is that it helps preserve tissue integrity, which means most patients can continue their planned chemotherapy schedule with minimal interruption. However, because Savene can cause myelosuppression (decreased blood cell counts), your oncology team will monitor your blood counts closely and may need to adjust the timing of subsequent chemotherapy cycles. The 3-day Savene treatment is a one-time intervention for each extravasation event and does not become part of your regular chemotherapy regimen.
Yes, dexrazoxane is the same active substance, but Savene is specifically formulated and approved for the treatment of anthracycline extravasation, not for cardioprotection. The cardioprotective form of dexrazoxane (marketed under different brand names such as Zinecard or Cardioxane) is used to prevent anthracycline-induced cardiotoxicity in certain patient populations. The two indications use different dosing regimens and formulations, and they should not be interchanged. Savene includes a specific diluent solution designed for the extravasation indication.
References
All medical information is based on peer-reviewed research, international guidelines, and official regulatory documents.
- European Medicines Agency (EMA). Savene — Summary of Product Characteristics. Last updated 2024. Available at: ema.europa.eu/en/medicines/human/EPAR/savene
- Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annals of Oncology. 2007;18(3):546-550. doi:10.1093/annonc/mdl413
- Langer SW. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Management and Research. 2014;6:357-363. doi:10.2147/CMAR.S47238
- European Society for Medical Oncology (ESMO). ESMO-EONS Clinical Practice Guidelines: extravasation management. Annals of Oncology. 2012;23(Suppl 7):vii167-vii173.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023. Geneva: World Health Organization.
- Pérez Fidalgo JA, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Annals of Oncology. 2012;23(suppl 7):vii167-vii173.
- British National Formulary (BNF). Dexrazoxane monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Totect (dexrazoxane) prescribing information. 2007. (Note: Totect is the US-marketed equivalent of Savene.)
Medical Editorial Team
This article has been written and reviewed by iMedic's medical editorial team, comprising board-certified specialists in oncology, clinical pharmacology, and emergency medicine.
All content follows the GRADE evidence framework. No commercial funding or pharmaceutical sponsorship. Read our editorial standards.